Abstract
Endogenous retrovirus antibody responses contribute to survival after immune checkpoint blockade therapy against lung adenocarcinoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1126/sciimmunol.adi8769
Copy DOIJournal: Science immunology | Publication Date: Jun 30, 2023 |
Endogenous retrovirus antibody responses contribute to survival after immune checkpoint blockade therapy against lung adenocarcinoma.
Join us for a 30 min session where you can share your feedback and ask us any queries you have